Top

Published in:

Open Access 01-03-2020 | Metastasis | Original Article

Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer

Authors: Caroline Bergenfelz, Anna Roxå, Meliha Mehmeti, Karin Leandersson, Anna-Maria Larsson

Published in: Cancer Immunology, Immunotherapy | Issue 3/2020

Abstract

The overall aim of this prospective study was to delineate the role of monocytic myeloid-derived suppressor cells (Mo-MDSCs) in patients with metastatic breast cancer (MBC). MDSCs are a heterogeneous group of immunosuppressive cells often enriched in different malignancies which hold prognostic and predictive value for clinical outcomes. Here, we assessed the clinical significance of Mo-MDSCs in 54 patients with de novo or distant recurrent MBC. We show that high levels of Mo-MDSCs significantly correlated with de novo MBC (metastatic disease at initial diagnosis), estrogen receptor (ER) negativity, and liver- and bone metastasis. A trend towards an association between high levels of Mo-MDSCs and survival (P = 0.053) was also found in patients with distant recurrent ER-positive MBC. We therefore propose that an increased population of Mo-MDSCs may be related to the metastatic or immunoregulatory switch associated with transition to a more systemic disease. Our data imply that high levels of systemic Mo-MDSCs represent patients with more aggressive disease and worse outcome.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68:394–424. Doi: 10.3322/caac.21492.

SweBCG (2018) Swedish Breast Cancer Group national guidelines. Available from http://www.swebcg.se

Tryggvadottir L, Gislum M, Bray F, Klint A, Hakulinen T, Storm HH, Engholm G (2010) Trends in the survival of patients diagnosed with breast cancer in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 49:624–631. https://doi.org/10.3109/02841860903575323 CrossRefPubMed

Cardoso F, Costa A, Senkus E et al (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncolog 28:16–33. https://doi.org/10.1093/annonc/mdw544 CrossRef

Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121:1–14. https://doi.org/10.1111/j.1365-2567.2007.02587.x CrossRefPubMedPubMedCentral

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565–1570. https://doi.org/10.1126/science.1203486 CrossRefPubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140:883–899. https://doi.org/10.1016/j.cell.2010.01.025 CrossRefPubMedPubMedCentral

Gabrilovich DI (2017) Myeloid-derived suppressor cells. Cancer Immunol Res 5:3–8. https://doi.org/10.1158/2326-6066.CIR-16-0297 CrossRefPubMedPubMedCentral

10.

Poschke I, Kiessling R (2012) On the armament and appearances of human myeloid-derived suppressor cells. Clin Immunol 144:250–268. https://doi.org/10.1016/j.clim.2012.06.003 CrossRefPubMed

11.

Cuenca AG, Delano MJ, Kelly-Scumpia KM, Moreno C, Scumpia PO, Laface DM, Heyworth PG, Efron PA, Moldawer LL (2011) A paradoxical role for myeloid-derived suppressor cells in sepsis and trauma. Mol Med 17:281–292. https://doi.org/10.2119/molmed.2010.00178 CrossRefPubMed

12.

Millrud CR, Bergenfelz C, Leandersson K (2017) On the origin of myeloid-derived suppressor cells. Oncotarget 8:3649–3665. https://doi.org/10.18632/oncotarget.12278 CrossRefPubMed

13.

Talmadge JE, Gabrilovich DI (2013) History of myeloid-derived suppressor cells. Nat Rev Cancer 13:739–752. https://doi.org/10.1038/nrc3581 CrossRefPubMedPubMedCentral

14.

Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9:162–174. https://doi.org/10.1038/nri2506 CrossRefPubMedPubMedCentral

15.

Wang PF, Song SY, Wang TJ, Ji WJ, Li SW, Liu N, Yan CX (2018) Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies. Oncoimmunology 7:e1494113. https://doi.org/10.1080/2162402X.2018.1494113 CrossRefPubMedPubMedCentral

16.

Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3rd (2013) Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat 140:13–21. https://doi.org/10.1007/s10549-013-2618-7 CrossRefPubMedPubMedCentral

17.

Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49–59. https://doi.org/10.1007/s00262-008-0523-4 CrossRefPubMed

18.

Foulds GA, Vadakekolathu J, Abdel-Fatah TMA et al (2018) Immune-phenotyping and transcriptomic profiling of peripheral blood mononuclear cells from patients with breast cancer: identification of a 3 gene signature which predicts relapse of triple negative breast cancer. Front Immunol 9:2028. https://doi.org/10.3389/fimmu.2018.02028 CrossRefPubMedPubMedCentral

19.

Gonda K, Shibata M, Ohtake T, Matsumoto Y, Tachibana K, Abe N, Ohto H, Sakurai K, Takenoshita S (2017) Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer. Oncol Lett 14:1766–1774. https://doi.org/10.3892/ol.2017.6305 CrossRefPubMedPubMedCentral

20.

Solito S, Falisi E, Diaz-Montero CM et al (2011) A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 118:2254–2265. https://doi.org/10.1182/blood-2010-12-325753 CrossRefPubMedPubMedCentral

21.

Wesolowski R, Duggan MC, Stiff A et al (2017) Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother 66:1437–1447. https://doi.org/10.1007/s00262-017-2038-3 CrossRefPubMedPubMedCentral

22.

Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R (2010) Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 70:4335–4345. https://doi.org/10.1158/0008-5472.CAN-09-37670008-5472.CAN-09-3767 [pii] CrossRefPubMed

23.

Filipazzi P, Valenti R, Huber V et al (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25:2546–2553. https://doi.org/10.1200/JCO.2006.08.582925/18/2546 [pii] CrossRefPubMed

24.

Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, Dietz AB (2010) Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 70:443–455. https://doi.org/10.1002/pros.21078 CrossRefPubMedPubMedCentral

25.

Gustafson MP, Lin Y, New KC, Bulur PA, O'Neill BP, Gastineau DA, Dietz AB (2010) Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro-Oncol 12:631–644. https://doi.org/10.1093/neuonc/noq001 CrossRefPubMedPubMedCentral

26.

Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB (2011) Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood 117:872–881. https://doi.org/10.1182/blood-2010-05-283820 CrossRefPubMedPubMedCentral

27.

Yuan XK, Zhao XK, Xia YC, Zhu X, Xiao P (2011) Increased circulating immunosuppressive CD14(+)HLA-DR(-/low) cells correlate with clinical cancer stage and pathological grade in patients with bladder carcinoma. J Int Med Res 39:1381–1391CrossRefPubMed

28.

Bergenfelz C, Larsson AM, von Stedingk K et al (2015) Systemic monocytic-MDSCs are generated from monocytes and correlate with disease progression in breast cancer patients. PLoS ONE 10:e0127028. https://doi.org/10.1371/journal.pone.0127028 CrossRefPubMedPubMedCentral

29.

Larsson AM, Jansson S, Bendahl PO, Levin Tykjaer Jorgensen C, Loman N, Graffman C, Lundgren L, Aaltonen K, Ryden L (2018) Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Breast Cancer Res 20:48. https://doi.org/10.1186/s13058-018-0976-0 CrossRefPubMedPubMedCentral

30.

Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. https://doi.org/10.1016/j.ejca.2008.10.026 CrossRefPubMed

31.

Cristofanilli M, Budd GT, Ellis MJ et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791. https://doi.org/10.1056/NEJMoa040766 CrossRefPubMed

32.

Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW (2004) Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 10:6897–6904. https://doi.org/10.1158/1078-0432.CCR-04-0378 CrossRefPubMed

33.

Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9:R15. https://doi.org/10.1186/bcr1648 CrossRefPubMedPubMedCentral

34.

Mehmeti M, Allaoui R, Bergenfelz C, Saal LH, Ethier SP, Johansson ME, Jirstrom K, Leandersson K (2015) Expression of functional toll like receptor 4 in estrogen receptor/progesterone receptor-negative breast cancer. Breast Cancer Res 17:130. https://doi.org/10.1186/s13058-015-0640-x CrossRefPubMedPubMedCentral

35.

Rashid OM, Nagahashi M, Ramachandran S, Graham L, Yamada A, Spiegel S, Bear HD, Takabe K (2013) Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surgery 153:771–778. https://doi.org/10.1016/j.surg.2013.02.002 CrossRefPubMed

36.

Gil Del Alcazar CR, Huh SJ, Ekram MB et al (2017) Immune escape in breast cancer during in situ to invasive carcinoma transition. Cancer Discov 7:1098–1115. https://doi.org/10.1158/2159-8290.CD-17-0222 CrossRefPubMedPubMedCentral

37.

Ouzounova M, Lee E, Piranlioglu R et al (2017) Monocytic and granulocytic myeloid derived suppressor cells differentially regulate spatiotemporal tumour plasticity during metastatic cascade. Nat Commun 8:14979. https://doi.org/10.1038/ncomms14979 CrossRefPubMedPubMedCentral

38.

Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Ryden L (2016) Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer 16:433. https://doi.org/10.1186/s12885-016-2406-y CrossRefPubMedPubMedCentral

39.

Szczerba BM, Castro-Giner F, Vetter M et al (2019) Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature 566:553–557. https://doi.org/10.1038/s41586-019-0915-y CrossRefPubMed

40.

Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev Cancer 9:239–252. https://doi.org/10.1038/nrc2618 CrossRefPubMed

41.

Shi H, Zhang J, Han X, Li H, Xie M, Sun Y, Liu W, Ba X, Zeng X (2017) Recruited monocytic myeloid-derived suppressor cells promote the arrest of tumor cells in the premetastatic niche through an IL-1beta-mediated increase in E-selectin expression. Int J Cancer 140:1370–1383. https://doi.org/10.1002/ijc.30538 CrossRefPubMed

42.

Pastaki Khoshbin A, Eskian M, Keshavarz-Fathi M, Rezaei N (2018) Roles of myeloid-derived suppressor cells in cancer metastasis: immunosuppression and beyond. Arch Immunol Ther Exp (Warsz). https://doi.org/10.1007/s00005-018-0531-9 CrossRef

43.

Ursini-Siegel J, Siegel PM (2016) The influence of the pre-metastatic niche on breast cancer metastasis. Cancer Lett 380:281–288. https://doi.org/10.1016/j.canlet.2015.11.009 CrossRefPubMed

44.

Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L (2017) Targeting immune checkpoints in breast cancer: an update of early results. ESMO Open 2:e000255. https://doi.org/10.1136/esmoopen-2017-000255 CrossRefPubMedPubMedCentral

45.

Katz H, Alsharedi M (2017) Immunotherapy in triple-negative breast cancer. Med Oncol 35:13. https://doi.org/10.1007/s12032-017-1071-6 CrossRefPubMed

46.

Schmid P, Adams S, Rugo HS et al (2018) Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 379:2108–2121. https://doi.org/10.1056/NEJMoa1809615 CrossRefPubMed

Title: Clinical relevance of systemic monocytic-MDSCs in patients with metastatic breast cancer
Authors: Caroline Bergenfelz
Anna Roxå
Meliha Mehmeti
Karin Leandersson
Anna-Maria Larsson
Publication date: 01-03-2020
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Breast Cancer
Breast Cancer
Estrogens
Published in: Cancer Immunology, Immunotherapy / Issue 3/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-019-02472-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2020

Retraction Note to: Bio‑HMGB1 from breast cancer contributes to M‑MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC‑like cells

The CD38low natural killer cell line KHYG1 transiently expressing CD16F158V in combination with daratumumab targets multiple myeloma cells with minimal effector NK cell fratricide

The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer

PCSK9 is a promising prognostic marker in patients with advanced NSCLC

Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer